[go: up one dir, main page]

CR20130190A - Inhibidores de apoptosis y usos de los mismos - Google Patents

Inhibidores de apoptosis y usos de los mismos

Info

Publication number
CR20130190A
CR20130190A CR20130190A CR20130190A CR20130190A CR 20130190 A CR20130190 A CR 20130190A CR 20130190 A CR20130190 A CR 20130190A CR 20130190 A CR20130190 A CR 20130190A CR 20130190 A CR20130190 A CR 20130190A
Authority
CR
Costa Rica
Prior art keywords
same
apoptosis inhibitors
apoptosis
inhibitors
Prior art date
Application number
CR20130190A
Other languages
English (en)
Inventor
Joel Nargeot
Bernard Lebleu
Stephanie Barrere
Prisca Boisguerin
Christophe Piot
Original Assignee
Centre Nat Rech Scient
Univ Montpellier 1
Univ Montpellier Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43880951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130190(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre Nat Rech Scient, Univ Montpellier 1, Univ Montpellier Ii filed Critical Centre Nat Rech Scient
Publication of CR20130190A publication Critical patent/CR20130190A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CR20130190A 2010-11-18 2013-05-02 Inhibidores de apoptosis y usos de los mismos CR20130190A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2010/003158 WO2012066376A1 (en) 2010-11-18 2010-11-18 Inhibitors of apoptosis and uses thereof

Publications (1)

Publication Number Publication Date
CR20130190A true CR20130190A (es) 2013-10-07

Family

ID=43880951

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130190A CR20130190A (es) 2010-11-18 2013-05-02 Inhibidores de apoptosis y usos de los mismos

Country Status (36)

Country Link
US (1) US9814758B2 (es)
EP (2) EP2640739B1 (es)
JP (1) JP6204828B2 (es)
KR (2) KR102017645B1 (es)
CN (2) CN106188271B (es)
AU (1) AU2011331103B2 (es)
BR (1) BR112013012362A2 (es)
CA (2) CA2816827C (es)
CL (1) CL2013001411A1 (es)
CO (1) CO6700879A2 (es)
CR (1) CR20130190A (es)
CY (1) CY1118022T1 (es)
DK (1) DK2640739T3 (es)
EA (1) EA027336B1 (es)
ES (2) ES2653734T3 (es)
GE (1) GEP201606514B (es)
GT (1) GT201300117A (es)
HR (1) HRP20151165T1 (es)
HU (1) HUE026150T2 (es)
IL (2) IL226005B (es)
MA (1) MA34670B1 (es)
ME (1) ME02291B (es)
MX (1) MX345594B (es)
MY (1) MY170604A (es)
NI (1) NI201300045A (es)
NZ (1) NZ610620A (es)
PH (1) PH12013500843A1 (es)
PL (1) PL2640739T3 (es)
PT (1) PT2640739E (es)
RS (1) RS54422B1 (es)
RU (1) RU2582247C2 (es)
SG (1) SG190681A1 (es)
SI (1) SI2640739T1 (es)
UA (1) UA112420C2 (es)
WO (2) WO2012066376A1 (es)
ZA (1) ZA201303042B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10632237B2 (en) 2006-10-09 2020-04-28 Minnetronix, Inc. Tangential flow filter system for the filtration of materials from biologic fluids
WO2012066376A1 (en) * 2010-11-18 2012-05-24 Centre National De La Recherche Scientifique - Cnrs - Inhibitors of apoptosis and uses thereof
GB201314610D0 (en) 2013-08-15 2013-10-02 Blueberry Therapeutics Ltd Compounds and their uses
CN103585618B (zh) * 2013-10-31 2016-04-06 中山大学 端粒结合蛋白daxx在制备肿瘤细胞调控剂中的应用
EP3714915B1 (en) 2015-08-05 2021-11-03 Minnetronix Inc. Tangential flow filter system for the filtration of materials from biologic fluids
CN108472332B (zh) * 2015-11-13 2022-03-18 汉阳大学校产学协力团 用于通过经鼻施用来治疗中风的组合物
US20210113649A1 (en) * 2018-04-05 2021-04-22 University Of Florida Research Foundation, Inc. Polypeptide inhibitor of de novo lipogenesis in cancer cells
CN108753820A (zh) * 2018-06-07 2018-11-06 嘉兴学院 Daxx蛋白通过激活erk信号通路促进卵巢癌腹水细胞增殖和转移
CN111499717B (zh) * 2020-04-10 2020-11-24 南京市儿童医院 一种脑源肽及其应用
CA3228169A1 (en) * 2021-08-06 2023-02-09 The Trustees Of The Univeristy Of Pennsylvania Compositions and methods for treatment and prevention of misfolded proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034946A1 (en) * 1997-02-12 1998-08-13 Massachusetts Institute Of Technology Daxx, a novel fas-binding protein that activates jnk and apoptosis
CA2437983C (en) * 2001-02-16 2011-10-25 Cellgate, Inc. Transporters comprising spaced arginine moieties
RU2328273C2 (ru) * 2001-12-19 2008-07-10 Рисерч Дивелопмент Фаундейшн Липосомальная доставка соединений, основанных на витамине е
KR100597615B1 (ko) * 2004-05-07 2006-07-10 주식회사 동부한농 인간 NHE1 이온채널 단백질 결합제로서의 인간Daxx 단백질 및 그의 단편
WO2010006177A2 (en) 2008-07-10 2010-01-14 Dana-Farber Cancer Institute, Inc. Muc1, caspase-8,and ded-containing proteins
WO2012066376A1 (en) * 2010-11-18 2012-05-24 Centre National De La Recherche Scientifique - Cnrs - Inhibitors of apoptosis and uses thereof

Also Published As

Publication number Publication date
RU2013127565A (ru) 2014-12-27
EP2982685B1 (en) 2017-11-15
GEP201606514B (en) 2016-07-25
US9814758B2 (en) 2017-11-14
AU2011331103A1 (en) 2013-05-23
RU2582247C2 (ru) 2016-04-20
SG190681A1 (en) 2013-07-31
PH12013500843A1 (en) 2013-06-24
WO2012066376A1 (en) 2012-05-24
KR102017645B1 (ko) 2019-09-03
US20130288979A1 (en) 2013-10-31
CN106188271A (zh) 2016-12-07
CO6700879A2 (es) 2013-06-28
ZA201303042B (en) 2014-07-30
CA2816827C (en) 2020-06-23
HUE026150T2 (en) 2016-05-30
EA201300592A1 (ru) 2013-10-30
IL226005B (en) 2018-02-28
IL257069A (en) 2018-03-29
MA34670B1 (fr) 2013-11-02
WO2012066103A2 (en) 2012-05-24
DK2640739T3 (en) 2015-12-07
WO2012066103A3 (en) 2012-08-16
PT2640739E (pt) 2015-11-30
CA2816827A1 (en) 2012-05-22
EP2640739A2 (en) 2013-09-25
IL226005A0 (en) 2013-06-27
UA112420C2 (uk) 2016-09-12
ME02291B (me) 2016-02-20
MX345594B (es) 2017-02-07
RS54422B1 (sr) 2016-04-28
CN106188271B (zh) 2019-11-26
AU2011331103B2 (en) 2016-11-24
IL257069B (en) 2019-09-26
CY1118022T1 (el) 2017-05-17
CN103403023B (zh) 2016-08-17
BR112013012362A2 (pt) 2016-08-30
PL2640739T3 (pl) 2016-01-29
EP2640739B1 (en) 2015-09-02
ES2653734T3 (es) 2018-02-08
NI201300045A (es) 2013-08-01
ES2553770T3 (es) 2015-12-11
CA3078178A1 (en) 2012-05-22
HRP20151165T1 (hr) 2015-12-18
KR101913285B1 (ko) 2018-10-30
CL2013001411A1 (es) 2014-03-28
CN103403023A (zh) 2013-11-20
KR20140032955A (ko) 2014-03-17
MY170604A (en) 2019-08-20
JP6204828B2 (ja) 2017-09-27
HK1184791A1 (zh) 2014-03-07
KR20180119697A (ko) 2018-11-02
GT201300117A (es) 2015-11-13
SI2640739T1 (sl) 2016-01-29
NZ610620A (en) 2015-01-30
EA027336B1 (ru) 2017-07-31
CA3078178C (en) 2023-07-11
EP2982685A1 (en) 2016-02-10
JP2013544249A (ja) 2013-12-12
MX2013005587A (es) 2014-02-03

Similar Documents

Publication Publication Date Title
CR20130168A (es) Moduladores de receptores de estrògenos y usos de los mismos
CO6821931A2 (es) Inhibidores selectivos de la glicosidasa y usos de los mismos
CR20130190A (es) Inhibidores de apoptosis y usos de los mismos
HRP20182037T1 (hr) Inhibitori prmt5 i njihova uporaba
CR20140259A (es) Compuestos novedosos de benzopirano, composiciones y usos de los mismos
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
MX314649B (es) Polimeros para depuracion de metales y usos de los mismos.
CO7030961A2 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PT2817338T (pt) Moduladores de dll3 e métodos de utilização
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
EP2928471A4 (en) HISTONDEMETHYLASE INHIBITORS
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
BR112014003774A2 (pt) inibidores de dyrk1 e usos dos mesmos
BR112014000445A2 (pt) usos de inibidores de hsp90 marcados
BR112013002845A2 (pt) combinação de susbtâncias ativas
DK2536722T3 (da) Bicycliske forbindelser og deres anvendelse som dual-c-src-/jak-inhibitorer
SI3715345T1 (sl) Priprava zaviralca lfa-1
CO7020913A2 (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
LT2786756T (lt) Derinių terapija su topoizomerazės inhibitoriumi
HRP20181695T1 (hr) Kristalni oblik inhibitora benzilbenzena sglt2
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
CO6870031A2 (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
HRP20182046T1 (hr) Uređaj za kuhanje i postupak njegove upotrebe
CO6801713A2 (es) Heteroarilos y sus usos
EP2911193A4 (en) COOLING STRUCTURE AND HEAT-GENERATING BODY